Alnylam Pharmaceuticals (ALNY) Insider Trading & Ownership $401.80 +9.56 (+2.44%) Closing price 08/1/2025 04:00 PM EasternExtended Trading$394.62 -7.18 (-1.79%) As of 08/1/2025 07:37 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Insider Trades Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock Alnylam Pharmaceuticals (NASDAQ:ALNY) Insider Buying and Selling ActivityCurrentInsider OwnershipPercentage1.50%Number OfInsiders Buying(Last 12 Months)0Number OfInsiders Selling(Last 12 Months)7Amount OfInsider Selling(Last 12 Months)$47.54M Get ALNY Insider Trade Alerts Want to know when executives and insiders are buying or selling Alnylam Pharmaceuticals stock? Sign up for InsiderTrades.com's daily newsletter to get the latest insider transactions delivered to your inbox daily. Email Address ALNY Insider Buying and Selling by Quarter Alnylam Pharmaceuticals Insider and Congressional Trades History Insiders and Members of Congress Insiders Only Members of Congress Only Transaction Type Custom Range 1 Month 3 Months 6 Months Year-to-Date 1 Year 2 Years 3 Years Time Frame Start Date End Date Export to Excel Transaction DateNameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails6/2/2025Yvonne GreenstreetCEOSell19,297$306.00$5,904,882.00 5/30/2025Yvonne GreenstreetCEOSell31,640$304.39$9,630,899.60 5/12/2025Jefferson ShreveU.S. Congress Member (R-IN)Sell$270.19$15,001 - $50,0002/18/2025Kevin Joseph FitzgeraldEVPSell1,440$251.56$362,246.40 2/18/2025Pushkal GargCMOSell1,548$251.67$389,585.16 2/14/2025Jeffrey V PoultonCFOSell967$255.17$246,749.39 2/14/2025Kevin Joseph FitzgeraldEVPSell663$255.21$169,204.23 2/14/2025Pushkal GargCMOSell1,561$255.17$398,320.37 2/14/2025Yvonne GreenstreetCEOSell1,213$255.17$309,521.21 1/27/2025Pushkal GargCMOSell52,592$285.00$14,988,720.00 1/23/2025Phillip A. SharpDirectorSell11,250$275.00$3,093,750.00 Get Insider Trades Delivered To Your InboxEnter your email address below to receive a concise daily summary of insider buying activity, insider selling activity and changes in hedge fund holdings. 12/12/2024Pushkal GargCMOSell1,752$251.00$439,752.00 11/26/2024Pushkal GargCMOSell1,682$250.98$422,148.36 11/26/2024Tolga TangulerEVPSell1,469$250.98$368,689.62 11/26/2024Yvonne GreenstreetCEOSell5,219$250.98$1,309,864.62 8/20/2024Yvonne GreenstreetCEOSell15,000$280.00$4,200,000.00 8/6/2024Dennis A AusielloDirectorSell20,250$262.00$5,305,500.00 8/1/2024Yvonne GreenstreetCEOSell15,148$270.00$4,089,960.00 (Data available from 1/1/2013 forward) ALNY Insider Trading Activity - Frequently Asked Questions Who is on Alnylam Pharmaceuticals' Insider Roster? The list of insiders at Alnylam Pharmaceuticals includes Akshay Vaishnaw, Amy W Schulman, David E I Pyott, Dennis A Ausiello, Indrani Lall Franchini, Jeffrey V Poulton, Kevin Joseph Fitzgerald, Michael W Bonney, Phillip A. Sharp, Pushkal Garg, Tolga Tanguler, and Yvonne Greenstreet. Learn more on insiders at ALNY. What percentage of Alnylam Pharmaceuticals stock is owned by insiders? 1.50% of Alnylam Pharmaceuticals stock is owned by insiders. Learn more on ALNY's insider holdings. Which Alnylam Pharmaceuticals insiders have been selling company stock? The following insiders have sold ALNY shares in the last 24 months: Amy W Schulman ($3,224,620.00), David E I Pyott ($7,161,390.50), Dennis A Ausiello ($5,305,500.00), Jeffrey V Poulton ($1,260,545.39), Kevin Joseph Fitzgerald ($808,176.65), Michael W Bonney ($5,850,000.00), Phillip A. Sharp ($3,093,750.00), Pushkal Garg ($18,533,610.45), Tolga Tanguler ($368,689.62), and Yvonne Greenstreet ($29,967,841.87). How much insider selling is happening at Alnylam Pharmaceuticals? Insiders have sold a total of 302,285 Alnylam Pharmaceuticals shares in the last 24 months for a total of $75,574,124.48 sold. Which members of congress are trading Alnylam Pharmaceuticals? Jefferson Shreve (R-IN) has sold shares of Alnylam Pharmaceuticals in the last year totaling $32,500. Alnylam Pharmaceuticals Key ExecutivesDr. Yvonne L. Greenstreet M.B.A. (Age 61)MBChB, CEO & Director Compensation: $2.15MMr. Jeffrey V. Poulton M.B.A. (Age 56)CFO & Executive VP Compensation: $1.05M1 recent tradesDr. Akshay K. Vaishnaw M.D. (Age 61)Ph.D., Chief Innovation Officer & Member of the Scientific Advisory Board Compensation: $1.12MDr. Pushkal P. Garg M.D. (Age 56)Chief Medical Officer and Executive VP of Development & Medical Affairs Compensation: $1.06MMr. Tolga Tanguler M.B.A. (Age 51)Executive VP & Chief Commercial Officer Compensation: $971.3kMr. Timothy J. MainesChief Technical Operations & Quality OfficerDr. Kevin Joseph Fitzgerald Ph.D. (Age 55)Senior VP, Head of Research & Chief Scientific Officer 2 recent tradesMs. Christine Regan Lindenboom (Age 43)Senior VP of Investor Relations & Corporate Communications Mr. Piyush Sharma J.D.Chief Ethics & Compliance OfficerMr. Evan Lippman M.B.A.Chief Corporate Development & Strategy Officer More Insider Trading Tools from MarketBeat Related Companies Amgen Insider Trades Gilead Sciences Insider Trades Vertex Pharmaceuticals Insider Trades Regeneron Pharmaceuticals Insider Trades Biogen Insider Trades Incyte Insider Trades United Therapeutics Insider Trades Neurocrine Biosciences Insider Trades Exelixis Insider Trades BioMarin Pharmaceutical Insider Trades Insider Tracking Tools CEO Purchases/Sales CFO Purchases/Sales Top Insider Buying Stocks Top Insider Selling Stocks Insider Trades Screener Insider Trades Newsletter Congressional Stock Trades Insider Trading By Country U.S. Insider Trading Activity Canadian Insider Trading Activity U.K. Insider Trading Activity Australia Insider Trading Activity Latest Articles The Bottom Is in For These 3 Small-Cap Stocks Insiders Are Buying3 Catalysts Driving Plug Power’s Turnaround CaseInsider Selling Hits Market Leaders—Should You Be Worried?Insiders Spent Millions on These 3 Stocks Over the Past 2 Months3 Small Caps Drawing Insider and Institutional Support This page (NASDAQ:ALNY) was last updated on 8/2/2025 by MarketBeat.com Staff From Our PartnersIs Elon's empire crumbling?The Tesla Shock Nobody Sees Coming While headlines scream "Tesla is doomed"... Jeff Brown has uncovered ...Brownstone Research | SponsoredBuffett to put 90% of his money in this one stock?CPA and CFA says you have WAY too many stocks - just buy these 3 After years working at the biggest accoun...Altimetry | SponsoredHe Called Nvidia at $1.10. Now, He Says THIS Stock Will…The original Magnificent Seven returned 16,894%—turning $7K into $1.18 million. Now, the man who called Nvi...The Oxford Club | SponsoredDigital Dollar Alert: Protect Your Wealth Before It’s Too Late134 countries are developing Central Bank Digital Currencies — and the U.S. is quietly testing one. Experts...American Alternative | SponsoredChina just unlocked Nvidia’s AI chips—what that means for youTired of Missing Big AI Moves Like Nvidia? You’re not the problem—your trading system is. Tim’s XGPT system...Timothy Sykes | SponsoredREVEALED FREE: Our top 3 stocks to own in 2025 and beyondEvery time Weiss Ratings flashed green like this, the average gain on each and every stock has been 303% (incl...Weiss Ratings | SponsoredWhy AMZN, GOOG, MSFT might destroy NVDAInvesting Legend Hints the End May be Near for These 3 Iconic Stocks Futurist Eric Fry say Amazon, Tesla an...InvestorPlace | SponsoredYour blueprint for crypto wealthMark August 12th on your calendar. 27 of crypto's most successful minds are about to reveal everything…Crypto 101 Media | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Alnylam Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Alnylam Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free ALNY Stock Alerts